Innovent Oncology

Innovent Biologics is a leading global biopharmaceutical company focused on developing, manufacturing, and commercializing high-quality innovative medicines for the treatment of oncology, metabolic, autoimmune, and ophthalmology diseases. The company's flagship product, Tyvyt (sintilimab), is a PD-1 inhibitor that has gained significant market share in China and is part of a broad collaboration with Eli Lilly. Innovent maintains a robust pipeline of over 30 clinical-stage assets, including bispecific antibodies and ADCs, supported by large-scale GMP-compliant manufacturing facilities. With a mission to provide affordable, high-quality biologics, the company has established itself as a premier partner for multinational pharmaceutical firms seeking to enter or expand in the Chinese market.